ArticleAnnals of clinical and translational neurology2026
Association Between Neurofilament Light Chain and Real-World Ambulatory Function in Progressive MS.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02936037 (Effect of MD1003 in Progressive Multiple Sclerosis), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Who cites it
1 citing paper in PubMed.
- Association Between Neurofilament Light Chain and Real-World Ambulatory Function in Progressive MS.Annals of clinical and translational neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveNeurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
methodsA post hoc analysis of the Phase III randomized controlled trial SPI2 (high-dose biotin vs. placebo RCT) pooled treatment arms due to no observed therapeutic benefit. Participants with sNfL and step count data were included. STEPS were calculated within ±15-days of baseline, 6, 12, 15, and 27-month visits. Mixed-effects models with 1000 bootstrap iterations assessed contemporaneous associations with each measure alternately specified as the outcome, adjusting for age and sex. Lagged models evaluated whether 0-6-month sNFL changes predicted subsequent 6-12-month STEPS changes.
resultsAmong 506 participants (53.8% female; mean age 52.7 [SD: 7.7] years; median EDSS 6.0 [4.5-6.0]), mean sNfL z-score was 1.00 (SD: 0.95), and median STEPS were 3029 [1708-5210]. Higher sNfL was associated with lower STEPS (IRR = 0.97, p = 0.014), consistent across sex, treatment, disability, and disease-modifying treatment status. Conversely, higher STEPS were associated with lower sNfL z-scores; a 10% increase in STEPS corresponded to a 0.015 decrease in sNfL z-score (95% CI -0.022 to -0.008; p < 0.001). Greater prior 6-month increases in sNfL were associated with a lower subsequent STEPS (β = -141; 95% CI -302 to 21; p = 0.088; trend), corresponding to 141 fewer steps per 1-SD sNfL increase.
interpretationHigher sNfL was associated with reduced daily ambulatory activity in progressive MS, and vice versa. Rising sNfL may precede mobility decline, highlighting sNfL as a potential indicator of functional worsening.
trial registrationClinicalTrials.gov NCT02936037; EudraCT database 2016-000700-29.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.